PHVS
Pharvaris N.V.
+0.62 (+1.65%)38.17USD406K成交股數–市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-12下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 22 · 9.2M · 6 |
| 其中 10b5-1 計畫賣出 | 22 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 16.5M |
| 近 180 天 淨額 | −16.5M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 | 09-17 | Souverijns Wim | Chief Commercial Officer | S 公開市場賣出(10b5-1) | 6.1K | 38.99 | 237K | 39.0K | SEC |
| 2026-09-14 | 09-17 | Souverijns Wim | Chief Commercial Officer | M 選擇權執行 | 20.0K | 17.43 | 349K | 65.1K | SEC |
| 2026-09-14 | 09-17 | Souverijns Wim | Chief Commercial Officer | S 公開市場賣出(10b5-1) | 20.0K | 39.31 | 786K | 45.1K | SEC |
| 2026-09-14 | 09-15 | Lu Peng | President | F 繳稅扣股 | 117 | 38.02 | 4K | 65.0K | SEC |
| 2026-09-14 | 09-15 | Modig Berndt | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.3K | 39.40 | 90K | 128K | SEC |
| 2026-09-11 | 09-15 | Lu Peng | President | F 繳稅扣股 | 109 | 37.51 | 4K | 65.1K | SEC |
| 2026-09-11 | 09-15 | Lu Peng | President | M 選擇權執行 | 15.0K | 2.59 | 39K | 80.2K | SEC |
| 2026-09-11 | 09-15 | Lu Peng | President | S 公開市場賣出(10b5-1) | 15.0K | 40.13 | 602K | 65.2K | SEC |
| 2026-09-10 | 09-14 | Lesage Anne | Chief Early Development | M 選擇權執行 | 30.0K | 8.05 | 242K | 86.5K | SEC |
| 2026-09-10 | 09-14 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 30.0K | 38.30 | 1.1M | 56.5K | SEC |
| 2026-09-09 | 09-11 | Glassman Robert | Director | M 選擇權執行 | 8.0K | 20.00 | 160K | 18.5K | SEC |
| 2026-09-09 | 09-11 | Glassman Robert | Director | S 公開市場賣出(10b5-1) | 8.0K | 37.55 | 300K | 10.5K | SEC |
| 2026-09-08 | 09-09 | Lu Peng | President | M 選擇權執行 | 15.0K | 2.59 | 39K | 80.2K | SEC |
| 2026-09-08 | 09-09 | Lu Peng | President | S 公開市場賣出(10b5-1) | 15.0K | 40.68 | 610K | 65.2K | SEC |
| 2026-08-14 | 08-18 | Modig Berndt | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.3K | 34.77 | 80K | 131K | SEC |
| 2026-08-12 | 08-13 | Lu Peng | President | F 繳稅扣股 | 117 | 34.42 | 4K | 65.2K | SEC |
| 2026-08-11 | 08-13 | Lu Peng | President | F 繳稅扣股 | 109 | 34.84 | 4K | 65.3K | SEC |
| 2026-07-13 | 07-15 | Modig Berndt | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.3K | 34.97 | 80K | 133K | SEC |
| 2026-07-12 | 07-14 | Lu Peng | Chief Medical Officer | F 繳稅扣股 | 117 | 35.07 | 4K | 65.4K | SEC |
| 2026-07-11 | 07-14 | Lu Peng | Chief Medical Officer | F 繳稅扣股 | 109 | 35.07 | 4K | 65.5K | SEC |
| 2026-06-30 | 07-01 | Schikan Johannes Gerardus Christiaan Petrus | Director | S 公開市場賣出(10b5-1) | 30.7K | 35.49 | 1.1M | 315K | SEC |
| 2026-06-30 | 07-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 3.0K | 2.59 | 8K | 61.7K | SEC |
| 2026-06-30 | 07-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 24.9K | 8.05 | 200K | 86.6K | SEC |
| 2026-06-30 | 07-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 27.9K | 35.48 | 989K | 58.8K | SEC |
| 2026-06-30 | 07-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 30.7K | 35.49 | 1.1M | 94.0K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 8.3K | 35.05 | 291K | 58.8K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 7.0K | 35.05 | 245K | 125K | SEC |
| 2026-06-29 | 07-01 | Schikan Johannes Gerardus Christiaan Petrus | Director | S 公開市場賣出(10b5-1) | 6.9K | 35.05 | 241K | 346K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 1.4K | 2.59 | 4K | 57.9K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 900 | 8.05 | 7K | 58.8K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 4.1K | 2.59 | 11K | 56.5K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 4.2K | 8.05 | 34K | 67.0K | SEC |
| 2026-06-29 | 07-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 2.3K | 35.12 | 81K | 56.5K | SEC |
| 2026-06-29 | 06-29 | Schikan Johannes Gerardus Christiaan Petrus | Director | S 公開市場賣出(10b5-1) | 2.4K | 35.10 | 84K | 353K | SEC |
| 2026-06-26 | 06-29 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 14.7K | 34.00 | 500K | 65.6K | SEC |
| 2026-06-26 | 06-29 | Lu Peng | Chief Medical Officer | M 選擇權執行 | 14.7K | 2.59 | 38K | 80.3K | SEC |
| 2026-06-25 | 06-29 | Lesage Anne | Chief Early Development | M 選擇權執行 | 1.4K | 2.59 | 4K | 57.9K | SEC |
| 2026-06-25 | 06-29 | Lesage Anne | Chief Early Development | M 選擇權執行 | 900 | 8.05 | 7K | 58.8K | SEC |
| 2026-06-25 | 06-29 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 2.3K | 35.12 | 81K | 56.5K | SEC |
| 2026-06-25 | 06-29 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 2.3K | 35.12 | 81K | 132K | SEC |
| 2026-06-25 | 06-29 | Lu Peng | Chief Medical Officer | M 選擇權執行 | 15.0K | 2.59 | 39K | 80.6K | SEC |
| 2026-06-25 | 06-29 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 11.6K | 34.45 | 400K | 69.0K | SEC |
| 2026-06-25 | 06-29 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 3.4K | 35.09 | 119K | 65.6K | SEC |
| 2026-06-18 | 06-23 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 300 | 34.00 | 10K | 65.6K | SEC |
| 2026-06-18 | 06-23 | Lu Peng | Chief Medical Officer | M 選擇權執行 | 300 | 2.59 | 777.00 | 65.9K | SEC |
| 2026-06-15 | 06-17 | Modig Berndt | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.2K | 31.05 | 68K | 135K | SEC |
| 2026-06-15 | 06-17 | Modig Berndt | Chief Executive Officer | S 公開市場賣出(10b5-1) | 100 | 31.46 | 3K | 135K | SEC |
| 2026-06-12 | 06-16 | Lu Peng | Chief Medical Officer | F 繳稅扣股 | 117 | 32.20 | 4K | 65.6K | SEC |
| 2026-06-11 | 06-15 | Lu Peng | Chief Medical Officer | F 繳稅扣股 | 109 | 31.51 | 3K | 65.7K | SEC |
| 2026-06-04 | 06-08 | Nijdam Anna | Principal Accounting Officer | S 公開市場賣出 | 2.7K | 30.87 | 82K | 46.3K | SEC |
| 2026-05-22 | 05-26 | Nijdam Anna | Principal Accounting Officer | S 公開市場賣出 | 5.5K | 30.74 | 169K | 48.9K | SEC |
| 2026-05-22 | 05-26 | Nijdam Anna | Principal Accounting Officer | M 選擇權執行 | 5.5K | 20.00 | 110K | 54.4K | SEC |
| 2026-05-21 | 05-26 | Nijdam Anna | Principal Accounting Officer | S 公開市場賣出 | 1.8K | 30.60 | 56K | 48.9K | SEC |
| 2026-05-21 | 05-26 | Nassif David W. | CFO / CLO | S 公開市場賣出 | 10.0K | 30.31 | 303K | 120K | SEC |
| 2026-05-21 | 05-26 | Nijdam Anna | Principal Accounting Officer | M 選擇權執行 | 1.8K | 20.00 | 37K | 50.8K | SEC |
| 2026-05-21 | 05-26 | Monges Viviane | Director | S 公開市場賣出 | 9.7K | 30.29 | 293K | 5.5K | SEC |
| 2026-05-20 | 05-22 | Bjork Elisabeth | Director | M 選擇權執行 | 10.0K | 8.05 | 81K | 25.2K | SEC |
| 2026-05-20 | 05-22 | Bjork Elisabeth | Director | S 公開市場賣出(10b5-1) | 10.0K | 29.32 | 293K | 15.2K | SEC |
| 2026-05-18 | 05-20 | Modig Berndt | Chief Executive Officer | S 公開市場賣出(10b5-1) | 2.3K | 29.22 | 67K | 138K | SEC |
| 2026-05-15 | 05-19 | Souverijns Wim | Chief Commercial Officer | S 公開市場賣出(10b5-1) | 10.0K | 29.92 | 299K | 45.1K | SEC |
| 2026-05-15 | 05-19 | Glassman Robert | Director | S 公開市場賣出 | 4.7K | 29.82 | 139K | 10.5K | SEC |
| 2026-05-15 | 05-19 | Glassman Robert | Director | S 公開市場賣出 | 5.3K | 29.83 | 159K | 15.2K | SEC |
| 2026-05-15 | 05-19 | Abele Stefan Andreas | Chief Technical Ops Officer | S 公開市場賣出 | 8.7K | 29.82 | 261K | 35.2K | SEC |
| 2026-05-15 | 05-19 | Glassman Robert | Director | M 選擇權執行 | 5.3K | 22.31 | 119K | 20.5K | SEC |
| 2026-05-12 | 05-13 | Lu Peng | Chief Medical Officer | F 繳稅扣股 | 117 | 29.95 | 4K | 65.9K | SEC |
| 2026-05-11 | 05-13 | Lu Peng | Chief Medical Officer | F 繳稅扣股 | 109 | 30.09 | 3K | 66.0K | SEC |
| 2026-05-01 | 05-05 | Lu Peng | Chief Medical Officer | M 選擇權執行 | 14.2K | 2.59 | 37K | 80.2K | SEC |
| 2026-05-01 | 05-05 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 14.0K | 30.16 | 423K | 66.2K | SEC |
| 2026-05-01 | 05-05 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 143 | 31.00 | 4K | 66.1K | SEC |
| 2026-04-30 | 05-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 18.0K | 8.05 | 145K | 74.5K | SEC |
| 2026-04-30 | 05-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 19.2K | 30.26 | 581K | 134K | SEC |
| 2026-04-30 | 05-01 | Schikan Johannes Gerardus Christiaan Petrus | Director | S 公開市場賣出(10b5-1) | 28.4K | 30.30 | 861K | 356K | SEC |
| 2026-04-30 | 05-01 | Schikan Johannes Gerardus Christiaan Petrus | Director | S 公開市場賣出(10b5-1) | 670 | 31.03 | 21K | 355K | SEC |
| 2026-04-30 | 05-01 | Lu Peng | Chief Medical Officer | M 選擇權執行 | 15.0K | 2.59 | 39K | 81.1K | SEC |
| 2026-04-30 | 05-01 | Lu Peng | Chief Medical Officer | S 公開市場賣出(10b5-1) | 15.0K | 30.24 | 454K | 66.1K | SEC |
| 2026-04-30 | 05-01 | Lesage Anne | Chief Early Development | M 選擇權執行 | 3.7K | 2.59 | 10K | 60.1K | SEC |
| 2026-04-30 | 05-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 3.7K | 30.26 | 112K | 56.5K | SEC |
| 2026-04-30 | 05-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 18.0K | 30.26 | 545K | 56.5K | SEC |
| 2026-04-29 | 05-01 | Lesage Anne | Chief Early Development | S 公開市場賣出(10b5-1) | 3.7K | 30.08 | 111K | 56.5K | SEC |
| 2026-04-29 | 05-01 | Lu Peng | Chief Medical Officer | M 選擇權執行 | 3.7K | 2.59 | 10K | 69.8K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 6.6M | 227M | +281K (+4%) | 加碼 |
| GENERAL ATLANTIC, L.P. | 6.6M | 227M | −1.5M (-18%) | 減碼 |
| Foresite Capital Management IV, LLC | 4.8M | 165M | 不變 | 持平 |
| venBio Partners LLC | 4.6M | 161M | +4.1K (+0%) | 加碼 |
| 維京環球 VIKING GLOBAL INVESTORS LP | 3.7M | 126M | 不變 | 持平 |
| EQT Fund Management S.a r.l. | 3.4M | 118M | 不變 | 持平 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.4M | 117M | +250K (+8%) | 加碼 |
| Bain Capital Life Sciences Investors, LLC | 2.7M | 92.5M | 不變 | 持平 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.4M | 82.7M | +274K (+13%) | 加碼 |
| Polar Capital Holdings Plc | 2.3M | 80.4M | +1.5M (+198%) | 加碼 |
| Point72(柯恩) Point72 Asset Management, L.P. | 1.6M | 56.8M | +634K (+63%) | 加碼 |
| Commodore Capital LP | 1.4M | 49.3M | −494K (-26%) | 減碼 |
| NOVO HOLDINGS A/S | 1.4M | 48.4M | −350K (-20%) | 減碼 |
| Saturn V Capital Management LP | 1.3M | 45.4M | +113K (+9%) | 加碼 |
| TCG Crossover Management, LLC | 1.0M | 34.9M | 新進 | 新進 |
| Sofinnova Investments, Inc. | 881K | 30.5M | +63.0K (+8%) | 加碼 |
| 5AM Venture Management, LLC | 798K | 27.6M | 不變 | 持平 |
| Seven Fleet Capital Management LP | 775K | 26.8M | +602K (+348%) | 加碼 |
| BlackRock, Inc. | 771K | 26.7M | +14.2K (+2%) | 加碼 |
| Cormorant Asset Management, LP | 750K | 25.9M | −250K (-25%) | 減碼 |
| Soleus Capital Management, L.P. | 731K | 25.3M | +28.9K (+4%) | 加碼 |
| Jones Hill Capital LP | 678K | 23.4M | +511K (+306%) | 加碼 |
| Patient Square Capital LP | 671K | 23.2M | +178K (+36%) | 加碼 |
| Foresite Capital Management V, LLC | 664K | 23.0M | +470K (+242%) | 加碼 |
| Kynam Capital Management, LP | 662K | 22.9M | +21.4K (+3%) | 加碼 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 125 +15 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 24 / 9 / 45 / 30 |
| 機構合計持股 · 佔流通股 | 64.7M |
| 合計季末市值 | 2.2B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 2.2M |
|---|---|
| 與上期比 | +21.7% |
| 佔流通股數 | –(外國發行人不算) |
| 日均成交量 | 639K |
| 回補天數 | 3.4 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 2.2M | +21.7% | – | 639K | 3.4 |
| 2026-08-14 | 1.8M | +48.7% | – | 638K | 2.8 |
| 2026-07-31 | 1.2M | +5.0% | – | 314K | 3.8 |
| 2026-07-15 | 1.1M | +15.3% | – | 676K | 1.7 |
| 2026-06-30 | 986K | -12.0% | – | 435K | 2.3 |
| 2026-06-15 | 1.1M | +58.0% | – | 378K | 3.0 |
| 2026-05-29 | 709K | +18.0% | – | 271K | 2.6 |
| 2026-05-15 | 601K | -42.9% | – | 464K | 1.3 |
| 2026-04-30 | 1.1M | -6.8% | – | 302K | 3.5 |
| 2026-04-15 | 1.1M | +58.4% | – | 225K | 5.0 |
| 2026-03-31 | 712K | -3.8% | – | 191K | 3.7 |
| 2026-03-13 | 740K | -1.5% | – | 154K | 4.8 |
| 2026-02-27 | 752K | -3.9% | – | 92.8K | 8.1 |
| 2026-02-13 | 782K | +4.7% | – | 127K | 6.2 |
| 2026-01-30 | 747K | -17.4% | – | 150K | 5.0 |
| 2026-01-15 | 904K | +22.2% | – | 240K | 3.8 |
| 2025-12-31 | 740K | +16.2% | – | 255K | 2.9 |
| 2025-12-15 | 637K | +43.7% | – | 654K | 1.0 |
| 2025-11-28 | 443K | -0.4% | – | 434K | 1.0 |
| 2025-11-14 | 445K | -16.4% | – | 225K | 2.0 |
| 2025-10-31 | 532K | -2.3% | – | 215K | 2.5 |
| 2025-10-15 | 545K | +0.7% | – | 186K | 2.9 |
| 2025-09-30 | 541K | +26.3% | – | 332K | 1.6 |
| 2025-09-15 | 428K | +5.7% | – | 116K | 3.7 |
| 2025-08-29 | 405K | -4.0% | – | 138K | 2.9 |
| 2025-08-15 | 422K | -5.4% | – | 102K | 4.2 |